This site is provided by Dr. Phil Berman who is going thru cancer treatment & has allowed other cancer survivors to create blogs about their situation. My personal blog regarding inflammatory breast cancer is at http://cbuerger.redtoenail.org. The blog site is easy to set up & maintain.
Excellent consensus weighted guidelines for treatment of thyroid cancer. Each guideline has been given a letter 'weighting' the level of consensus/professional agreement. Worthwhile reading for all thyroid cancer patients.
Survivor story of a nurse diagnosed with Signet Ring Appendiceal Cancer. Site lists information and resources about appendix cancer, treatment options and also identifies specialists treating this rare cancer. Offers additional information about clinical trials, means for obtaining assistance with medical travel and practical advice for dealing with insurance and billing issues.
Theme of this video is "I may have cancer but cancer does not have me!" It is a series of photos set to music with text. Very nicely done and shows a deep understanding of survival.
Therapeutic aids that help children dealing with hair loss. Helps them regain their confidence and self-image, and your child will have a comfortable friend that they identify with to help them feel good about themselves without hair. Helps on an emotional and psychological level. Also helpful as an avenue for communication in schools, groups, and social settings.
A very useful, informative book. Covers things to know at diagnosis, chosing a Physician , treatment,
re-ocurrence and end of life issues.
As we enter the era of "personalized" medicine, it is time to take a fresh look at how we evaluate treatments for cancer patients. More emphasis should be put on matching treatment to the patient. Patients would certainly have a better chance of success had their cancer been chemo-sensitive rather than chemo-resistant, where it is more apparent that chemotherapy improves the survival of patients, and where identifying the most effective chemotherapy would be more likely to improve survival.
Findings presented at the 41st Annual Meeting of the European Society for Clinical Investigation in Uppsala, Sweden, April 18, 2007, concluded that "functional profiling" with cell culture assays is relevant for the study of both "conventional" and "targeted" anti-neoplastic drug agents (anti-tumor and anti-angiogenic activity of Iressa, Tarceva, Sutent, Nexavar, and Avastin in primary cultures of "fresh" human tumors).
Cell Culture Assays with "cell-death" endpoints can show disease-specific drug activity, are useful clinical and research tools for "conventional" and "targeted" drugs, and provide unique information complementary to that provided by "molecular" tests. There have been more than 25 peer-reviewed publications showing significant correlations between cell-death assay results and patient response and survival.
Many patients are treated not only with a "targeted" therapy drug like Tarceva, Avastin, or Iressa, but with a combination of chemotherapy drugs. Therefore, existing DNA or RNA sequences or expression of individual proteins often examine only one compenent of a much larger, interactive process. The oncologist might need to administer several chemotherapy drugs at varying doses because tumor cells express survival factors with a wide degree of individual cell variability.
There is a tactic of using biopsied cells to predict which cancer treatments will work best for the patient, by taking pieces of live "fresh" tumor tissue, applying different chemotherapy treatments to it, and examining the results to see which drug or combination of drugs does the best job killing the tumor cells. A cell culture assay test with "functional profiling," using a cell-death endpoint, can help see what treatments will not have the best opportunity of being successful (resistant) and identify drugs that have the best opportunity of being successful (sensitive).
"Funtional profiling" measures the response of the tumor cells to drug exposure. Following this exposure, they measure both cell metabolism and cell morphology. The integrated effect of the drugs on the whole cell, resulting in a cellular response to the drug, measuring the interaction of the entire genome. No matter which genes are being affected, "functional profiling" is measuring them through the surrogate of measuring if the cell is alive or dead.
For example, the epidermal growth factor receptor (EGFR) is a protein on the surface of a cell. EGFR-inhibiting drugs certainly do target specific genes, but even knowing what genes the drugs target doesn't tell you the whole story. Both Iressa and Tarceva target EGFR protein-tyrosine kinases. But all the EGFR mutation or amplificaton studies can tell us is whether or not the cells are potentially susceptible to this mechanism of attack. They don't tell you if Iressa is better or worse than Tarceva or other drugs which may target this. There are differences. The drugs have to get inside the cells in order to target anything. So, in different tumors, either Iressa or Tarceva might get in better or worse than the other. And the drugs may also be inactivated at different rates, also contributing to sensitivity versus resistance.
As an example of this testing, researchers have tested how well a pancreatic cancer patient can be treated successfully with a combination of drugs commonly used to fight lung, pancreatic, breast, and colorectal cancers. The pre-test can report prospectively to a physician specifically which chemotherapy agent would benefit a cancer patient. Drug sensitivity profiles differ significantly among cancer patients even when diagnosed with the same cancer.
The "funtional profiling" technique makes the statistically significant association between prospectively reported test results and patient survival. It can correlate test results that are obtained in the lab and reported to physicians prior to patient treatment, with significantly longer or shorter overall patient survival depending upon whether the drug was found to be effective or ineffective at killing the patient's tumor cells in the laboratory.
This could help solve the problem of knowing which patients can tolerate costly new treatments and their harmful side effects. These "smart" drugs are a really exciting element of cancer medicine, but do not work for everyone, and a test to determine the efficacy of these drugs in a patient could be the first crucial step in personalizing treatment to the individual.
This song: Friends Like Mine
represents a volunteer campaign supporting the fight against Cancer. Written by a Cancer survivor, it was inpired by the the American Cancer Society Relay for Life.
This site is provides a program that you can use to help make healthful changes in your eating and exercise habits designed to help prevent cardiovascular disease.
The story of New Zealand six-time cancer survivor Phil Kerslake. Describes his inspiring life story, having battled both Hodgkin's and non-Hodgkin's lymphomas over 26 years. Details his chemotherapy, radiotherapy, eight operations including his spleen removal and host of other challenges along the way to his final full remission. Also describes his 2006 book about how to get mind, body and spirit aligned to recovery: Life, happiness ... and cancer: survive with action and attitude! (author's website at www.lifepaths.co.nz).